34127-22-5

Basic information

• Product Name: ETHYL 3,6-DICHLOROPYRIDAZINE-4-CARBOXYLATE
• Synonyms: 3,6-Dichloropyridazine-4-carboxylic acid ethyl ester;ETHYL 3,6-DICHLOROPYRIDAZINE-4-CARBOXYLATE;4-Pyridazinecarboxylic acid, 3,6-dichloro-, ethyl ester
• CAS NO: 34127-22-5
• Molecular Formula: C₇H₆Cl₂N₂O₂
• Molecular Weight: 221.04074
• Mol File: 34127-22-5.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 364.2±37.0 °C(Predicted)
• Appearance: /
• Density: 1.433±0.06 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• PKA: -3.52±0.10(Predicted)
• CAS DataBase Reference: ETHYL 3,6-DICHLOROPYRIDAZINE-4-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 3,6-DICHLOROPYRIDAZINE-4-CARBOXYLATE(34127-22-5)
• EPA Substance Registry System: ETHYL 3,6-DICHLOROPYRIDAZINE-4-CARBOXYLATE(34127-22-5)

Safety Data

• Hazardous Substances Data: 34127-22-5(Hazardous Substances Data)

Usage

General Description

Ethyl 3,6-dichloropyridazine-4-carboxylate is a chemical compound with the molecular formula C8H7Cl2N3O2. It is an ester derivative of 3,6-dichloropyridazine-4-carboxylic acid and is used in the synthesis of pharmaceuticals and agrochemicals. ETHYL 3,6-DICHLOROPYRIDAZINE-4-CARBOXYLATE is a white to off-white solid with a molecular weight of 242.07 g/mol. It is considered to be a hazardous chemical and should be handled and stored with proper precautions to avoid potential health and environmental risks.

Upstream product

• 19064-64-3 3,6-dichloro-4-methylpyridazine 
• 64-17-5 ethanol 
• 51149-08-7 3,6-dichloropyridazin-4-carboxylic acid 
• 5754-18-7 3,6-dihydroxy-4-methylpyridazine 
• 96042-30-7 4-(dicyanomethylene)-2-methyl-6-(p-dimethylaminostyryl)-4H-pyran 

Relevant articles and documents

GSK-3 INHIBITORS

The disclosure generally relates to compounds of formula (I), including their salts, as well as compositions and methods of using the compounds to treat disorders associated with GSK-3.

FUSED HETEROCYCLIC 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS

Novel compounds are provided which are 1 1 -beta-hydroxysteroid dehydrogenase type I inhibitors. 1 1-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 1 1-beta-hydroxys

PYRIDAZINIL QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF TUMOURS

The invention concerns quinazoline derivatives of Formula (I) wherein Z is an O, S, SO, SO2, N(R2) or C(R2)(R3) group wherein each R2 or R3 group is hydrogen or (1-8C)alkyl, m is 1, 2 or 3, each R1 group has any of the meanings defined in the description, Ra is halogeno or (1-6C)alkoxy, Rb is halogeno or (1-6C)alkoxy, and Rc is hydrogen, halogeno, (1-8C)alkyl or (1-6C)alkoxy, or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease.